Mizuho Reiterates Neutral on Corvus Pharma, Maintains $3.5 Price Target
Portfolio Pulse from richadhand@benzinga.com
Mizuho analyst Mara Goldstein has reiterated a Neutral rating on Corvus Pharma (NASDAQ:CRVS) and maintained a $3.5 price target.
June 16, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mizuho analyst Mara Goldstein reiterated a Neutral rating on Corvus Pharma (NASDAQ:CRVS) and maintained a $3.5 price target.
The news directly mentions Corvus Pharma (CRVS) and the analyst's Neutral rating and price target. This reaffirms the current market sentiment, but does not provide any new information or catalysts for significant price movement. Therefore, the short-term impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100